- Company
- Celltrion’s Remsima SC was approved in the US
- by Chon, Seung-Hyun Oct 24, 2023 05:22am
- On the 23rd, Celltrion announced that it had received marketing authorization for Zymfentra, which is a subcutaneous formulation of its antibody biosimilar Remsima. Remsima is a Remicade biosimilar. Zymfentra has been approved in Europe under the product name Remsima SC. Celltrion said, “Zymfentra is the world’s only infliximab SC f
- Policy
- Severe asthma txs Nucala and Cinqair are to be reimbursed
- by Lee, Jeong-Hwan Oct 24, 2023 05:22am
- Reimbursement treatment options for the treatment of severe eosinophilic asthma are expanded. GSK Korea's Nucala and Handok Teva Cinqair will be listed on the payroll simultaneously next month. Eisai's JAK inhibitor Jyseleca will also have new insurance coverage standards, and Novartis' JAK1/JAK2 inhibitor Jakavi will have coverage standards
- Company
- CMV treatment Livtencity can be prescribed at general hosp
- by Eo, Yun-Ho Oct 24, 2023 05:21am
- The cytomegalovirus treatment ‘Livtencity’ can now be prescribed at general hospitals in Korea. According to industry sources, Takeda Pharmaceuticals Korea’s Livtencity has passed the Drug Committees (DCs) of tertiary hospitals in Korea including Samsung Medical Center, Saint Mary's Hospital, Asan Medical Center, and Sinchon Severance H
- Policy
- TZD combined DPP4i-SGLT2i complex
- by Lee, Tak-Sun Oct 24, 2023 05:21am
- Due to the expansion of the reimbursement standards for combination diabetes drugs, combination drugs combining TZD-based ingredients with DPP4i or SGLT2i are expected to be released in November. Most of these products are combination drugs combining the DPP4i series Sitagliptin. According to the industry on the 23rd, TZD combination drugs s
- Company
- Next-generation antibiotic Zavicefta can be prescribed
- by Eo, Yun-Ho Oct 23, 2023 05:14am
- The new antibiotic drug Zabicefta is entering the prescription range of general hospitals. According to related industries, Pfizer Pharmaceuticals Korea's Zavicefta is being used in tertiary general hospitals such as SMC, Seoul St. Mary's Hospital, Asan Medical Center in Seoul, and Sinchon Severance Hospital, as well as Gangnam Severance
- Company
- New anemia tablets offer increased options
- by Nho, Byung Chul Oct 23, 2023 05:14am
- Whether the introduction of tablet formulations that offer improved convenience in intake in the KRW 100 billion renal anemia treatment market will shift the market paradigm and offer new options for anemia patients is gaining attention. Until now, erythropoietin stimulating agents were the mainstream treatment for anemia caused by chro
- Company
- Forxiga generics take over 30% of market in 6 mths
- by Kim, Jin-Gu Oct 23, 2023 05:14am
- Generic versions of ‘Forxiga (dapagliflozin)’ have increased their share in the market to 30% in half a year since the original Forxiga’s patent expiry. Since April of last year, 63 companies have been fiercely competing in the market after concurrently releasing their respective generic versions, and Boryung Pharmaceutical, Hanmi P
- Company
- Reimb pricing negotiations for Luxturna start in KOR
- by Eo, Yun-Ho Oct 23, 2023 05:14am
- The one-shot retinal dystrophy treatment ‘Luxturna’ has entered its last stage to reimbrursement in Korea. According to industry sources, Novartis Korea recently entered drug pricing negotiations for its Inherited Retinal Dystrophy (IRD) treatment Luxturna (voretigene neparvovec) with the National Health Insurance Service. Luxturna
- Company
- The DPP4i+SGLT2i diabetes combination drug market
- by Kim, Jin-Gu Oct 23, 2023 05:14am
- The market for diabetes two-drug combination drugs that combine DPP-4 inhibitors and SGLT-2 inhibitors appears to be growing slowly despite the expansion of combination benefits at the beginning of the year. Since last May, two-ingredient combination drugs have appeared on the market one after another, but the cumulative prescriptions for re
- Policy
- Announcement of dual pricing system
- by Lee, Jeong-Hwan Oct 20, 2023 05:32am
- The Ministry of Health and Welfare is expected to include the application of a refund-type risk-sharing system for innovative new drugs in the plan to provide appropriate information on the innovative value of new drugs to be announced soon. In order to improve accessibility to rare disease treatments, the company announced its position to c
